Loading
NASDAQHealthcareBiotechnology
Latest quote
$81.06
+$3.78 · +4.89%
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Regular session
$81.06
+$3.78 · +4.89%
Regular session · ET · Market data may be delayed.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Day range
Current $81.06
52-week range
Current $81.06
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
67
Bullish
Risk
38
Moderate Risk
Momentum
63
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Day range
Current $81.06
52-week range
Current $81.06
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 83K USD | 27K USD | 111K USD | 114K USD | 91K USD |
| Gross profit | −83K USD | −27K USD | −111K USD | −114K USD | −91K USD |
| Research and development | 100.64M USD | 75.06M USD | 1.01M USD | 4.46M USD | 13.83M USD |
| Selling, general, and administrative | 21.33M USD | 13.04M USD | 6.17M USD | 5.26M USD | 5.41M USD |
| Operating expenses | 121.97M USD | 88.1M USD | 7.19M USD | 9.73M USD | 19.24M USD |
| Interest income | 16.63M USD | 5.86M USD | 1.96M USD | 675K USD | — |
| Interest expense | — | 1.47M USD | — | — | — |
| Depreciation and amortization | 83K USD | 27K USD | 111K USD | 114K USD | 91K USD |
| Operating income | −122.05M USD | −88.12M USD | −7.3M USD | −9.84M USD | −19.34M USD |
| Net income | −105.43M USD | −83.72M USD | −5.34M USD | −9.93M USD | −19.32M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 29, 2024 | $1.613Special | Aug 26, 2024 | — |
Ex-dividend Aug 29, 2024
$1.613
Special
Record Aug 26, 2024
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
